Structure of 5-Azacytidine
CAS No.: 320-67-2
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
5-Azacytidine is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping DNA methyltransferases.
Synonyms: Azacitidine; 5-AzaC; WR 183027
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Systematic analysis of gut bacterial carcinogen metabolism and its functional consequences
Boyao Zhang ; George-Eugen Maftei ; Bartosz Bartmanski ; Michael Zimmermann ;
Abstract: Organic carcinogens, in particular DNA-reactive compounds, contribute to the irreversible initiation step of tumorigenesis through introduction of genomic instability. Although carcinogen bioactivation and detoxification by human enzymes has been extensively studied, carcinogen biotransformation by human-associated bacteria, the microbiota, has not yet been systematically investigated. We tested the biotransformation of 68 mutagenic carcinogens by 34 bacterial species representative for the upper and lower human gastrointestinal tract and found that the majority (41) of the tested carcinogens undergo bacterial biotransformation. To assess the functional consequences of microbial carcinogen metabolism, we developed a pipeline to couple gut bacterial carcinogen biotransformation assays with Ames mutagenicity testing and liver biotransformation experiments. This revealed a bidirectional crosstalk between gut microbiota and host carcinogen metabolism, which we validated in gnotobiotic mouse models. Overall, the systematic assessment of gut microbiota carcinogen biotransformation and its interplay with host metabolism highlights the gut microbiome as an important modulator of exposome-induced tumorigenesis.
Show More >
Purchased from AmBeed: 446-86-6 ; 121-66-4 ; 607-35-2 ; 67-20-9 ; 105650-23-5 ; 59-87-0 ; 117-39-5 ; 57-97-6 ; 5131-60-2 ; 512-56-1 ; 62-44-2 ; 6959-48-4 ; 84-65-1 ; 137-17-7 ; 117-39-5 ; 153-78-6 ; 1614-12-6 ; 298-81-7 ; 404-86-4 ; 320-67-2 ; 99-55-8 ; 94-52-0 ; 2832-40-8 ; 101-61-1 ; 103-33-3 ; 114-83-0 ; 64091-91-4 ; 53-96-3 ; 3817-11-6 ; 90-94-8 ; 613-13-8 ; 56-57-5 ; 91-64-5 ; 26148-68-5 ; 101-80-4 ; 139-65-1 ; 366-70-1 ; 389-08-2 ; 99-59-2 ; 132-32-1 ; 394-69-4 ; 3544-23-8 ; 389-08-2 ; 320-67-2 ; 82-28-0 ; 2475-45-8 ; 129-15-7
Show More >
CAS No. : | 320-67-2 |
Formula : | C8H12N4O5 |
M.W : | 244.20 |
SMILES Code : | OC[C@@H]1[C@H]([C@H]([C@H](N2C(N=C(N=C2)N)=O)O1)O)O |
Synonyms : |
Azacitidine; 5-AzaC; WR 183027
|
MDL No. : | MFCD00006539 |
InChI Key : | NMUSYJAQQFHJEW-KVTDHHQDSA-N |
Pubchem ID : | 9444 |
GHS Pictogram: |
![]() ![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335-H351-H361 |
Precautionary Statements: | P261-P305+P351+P338 |
Target |
|
In Vitro:
Concentration | Treated Time | Description | References |
LLC1 cells | 100nM | 72 h | To evaluate the effect of 5-Azacytidine on the proliferation of LLC1 cells, results showed that 100nM 5-Azacytidine had limited effect on cell proliferation. | PMC8765085 |
HNM007 cells | 100nM | 72 h | To evaluate the effect of 5-Azacytidine on the proliferation of HNM007 cells, results showed that 100nM 5-Azacytidine had limited effect on cell proliferation. | PMC8765085 |
4T1 cells | 100nM | 72 h | To evaluate the effect of 5-Azacytidine on the proliferation of 4T1 cells, results showed that 100nM 5-Azacytidine had limited effect on cell proliferation. | PMC8765085 |
Primary murine kidney fibroblasts | 100 or 150 μg/ml | 1 or 2 days | 5′-Azacytidine effectively de-methylated Rasal1 and rescued endogenous Rasal1 expression, normalizing the proliferative activity of fibrotic renal fibroblasts. | PMC4337426 |
ERC cells | 10 µM | 24 h | Induce differentiation of ERC cells into cardiomyocytes | PMC2212625 |
human cardiac stem cells (hCSCs) | 10 μM | 9 days | 5-Azacytidine inhibits DNA methylation, leading to decreased levels of DNMT3a and SIRT1, thereby affecting epigenetic modifications and autophagy | PMC9188476 |
THP-1 cells | 10 μM | 24 h | 5-Azacytidine effectively blocked the LPS-induced upregulation of DNMT3b, increased PPARγ expression, and reduced IL-1β expression. | PMC11600256 |
NSCLC cell lines | 500 nM | 24 h daily for 11 days | To investigate the effect of 5-Azacytidine in combination with HDAC inhibitors (e.g., ITF-2357) on the proliferation of NSCLC cells, results showed that the combination significantly inhibited cell proliferation. | PMC5808406 |
A549 and H460 cells | 500 nM | 11 days | To investigate the inhibitory effect of 5-Azacytidine in combination with ITF-2357 on the proliferation of A549 and H460 cells, results showed that the combination significantly inhibited cell proliferation. | PMC5808406 |
medaka fibroblast cells | 2 μM | 5 days | 5-Azacytidine was used to reactivate the expression of Teratorn genes. The results showed that 5-azacytidine treatment moderately increased the expression of some Teratorn genes, although the expression level of most genes remained low. | PMC5601938 |
OCI-LY1 | 0.3 µM | 3 days | 5-Azacytidine enhanced the sensitivity of OCI-LY1 cells to cisplatin, but the effect was less significant compared to other cell lines. | PMC10155448 |
SU-DHL2 | 0.3 µM | 3 days | 5-Azacytidine significantly enhanced the sensitivity of SU-DHL2 cells to cisplatin, reducing the IC50 value below the clinically achievable concentration. | PMC10155448 |
SU-DHL8 | 0.3 µM | 3 days | 5-Azacytidine significantly enhanced the sensitivity of SU-DHL8 cells to cisplatin, reducing the IC50 value below the clinically achievable concentration. | PMC10155448 |
T-HEp3 cells | 5 nM | 48 hours | AZA+atRA reprogramming inhibited the growth of T-HEp3 cells | PMC10592471 |
4T1 cells | 5 nM | 48 hours | AZA+atRA reprogramming inhibited the growth of 4T1 cells | PMC10592471 |
In Vivo:
Administration | Dosage | Frequency | Description | References |
Mice | Balb/c mice | Intraperitoneal injection | 5 mg/kg | Following the specified schedule | Inhibit DNMT1 to reduce CTX-induced myeloid cell expansion | PMC7868404 |
mice | LLC and HNM007 pulmonary metastasis models | subcutaneously injected | 0.5mg/kg | daily for 14 days | To evaluate the effect of 5-Azacytidine on pulmonary metastasis models, results showed that low dose 5-Azacytidine inhibited the accumulation of MDSCs in the lung and prolonged disease-free and overall survival. | PMC8765085 |
Mice | Unilateral ureteral obstruction (UUO) model | Intraperitoneal injection | 10 mg/kg | Every other day until the indicated time points | 5′-Azacytidine significantly ameliorated renal fibrosis in mice, reduced fibrotic areas and fibroblast accumulation, and restored Rasal1 expression. | PMC4337426 |
mice | LPS-induced acute lung injury model | intraperitoneal injection | 1 mg/kg | once daily for 3 days | 5-Azacytidine significantly alleviated LPS-induced lung tissue damage and alveolar-capillary barrier injury, and reduced inflammatory cytokine levels in BAL fluid. | PMC11600256 |
Mice | NOD/SCID mouse model | Intraperitoneal injection | 0.5 mg/kg | Every 14 days for a total of 28 days | To investigate the anti-tumor effect of 5-Azacytidine in combination with ITF-2357 in a NSCLC mouse model, results showed that the combination significantly reduced tumor volume and weight. | PMC5808406 |
Nude mice | OCI-LY1 and SU-DHL2 xenograft models | Intraperitoneal injection | 0.5 mg/kg | Once daily for 5 consecutive days | 5-Azacytidine significantly enhanced the cytotoxic effect of cisplatin in the SU-DHL8 xenograft model, but the effect was not significant in the OCI-LY1 model. | PMC10155448 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT02985190 | MDS|Systemic Autoimmune Diseas... More >>es Less << | PHASE2 | COMPLETED | 2022-08-30 | CHU Amiens, Amiens cedex 01, 8... More >>0054, France|CHU d'Angers, Angers cedex 9, 49933, France|Centre hospitalier Victor Dupouy, Argenteuil, 95107, France|CH Henri Duffaut d'Avignon, Avignon, 84000, France|Centre hospitalier de la C?te Basque, Bayonne cedex, 64109, France|H?pital Nord Franche-Comté, Belfort, 90015, France|H?pital Avicenne, Bobigny, 93009, France|Centre Hospitalier de Boulogne Sur Mer, Boulogne-sur-Mer, 62321, France|CHRU de Brest - H?pital Morvan, Brest, 29609, France|CHU C?te de Nacre, Caen, 14033, France|CH René Dubos, Cergy-Pontoise, 95303, France|Centre Hospitalier William Morey, Chalon-sur-Sa?ne, 71100, France|CHU Estaing, Clermont-Ferrand, 63000, France|CHSF Gilles de Corbeil, Corbeil-Essonnes, 91100, France|CHU Henri Mondor, Créteil, 94010, France|CHU Fran?ois Mitterrand, Dijon, 21079, France|CHU de Grenoble, Grenoble cedex 09, 38043, France|Groupe Hospitalier de la Rochelle Ré Aunis, La Rochelle, 17000, France|CH Le Mans, Le Mans cedex 09, 72037, France|Clinique Victor Hugo - Centre Jean Bernard, Le Mans, 72000, France|Centre Hospitalier de Lens, Lens, 62307, France|H?pital Claude Huriez, Lille cedex, 59037, France|H?pital Saint Vincent de Paul, Lille, 59020, France|CHRU de Limoges - H?pital Dupuytren, Limoges, 87042, France|Institut Paoli Calmettes, Marseille, 13273, France|Centre Hospitalier de Meaux, Meaux cedex, 77104, France|CH de Mont de Marsan, Mont-de-Marsan, 40000, France|Clinique Beausoleil, Montpellier, 34000, France|CHRU de Montpellier - Service de Médecine Interne, Montpellier, 34295, France|CHU de Montpellier - Service d'hématologie Oncologie, Montpellier, 34295, France|CHU Nantes - H?tel Dieu, Nantes cedex 1, 44093, France|Centre Catherine de Sienne, Nantes, 44277, France|H?pital Archet 1, Nice cedex 3, 06202, France|Centre Antoine Lacassagne, Nice, 06189, France|CHU de N?mes, N?mes cedex 9, 30029, France|CHR d'Orléans, Orléans, 45067, France|H?pital Saint-Louis, Paris, 75010, France|H?pital Saint Antoine - Service de Médecine Interne, Paris, 75012, France|H?pital de La Pitié-Salpêtrière, Paris, 75013, France|H?pital Saint Antoine - Service d'Hématologie Clinique, Paris, 75571, France|H?pital Cochin, Paris, 75679, France|H?pital Necker, Paris, 75743, France|Centre Hospitalier Joffre, Perpignan, 66 046, France|CHU de Haut-Lévèque, Pessac, 33604, France|Centre Hospitalier Lyon-Sud, Pierre-Bénite, 69495, France|CHU de Poitiers, Poitiers, 86021, France|Centre Hospitalier Annecy Genevois, Pringy, 74374, France|CHU de Reims, Reims, 51092, France|H?pital PONTCHAILLOU, Rennes, 35033, France|Centre Hospitalier de Rochefort, Rochefort, 17301, France|Centrer Hospitalier de Roubaix, Roubaix, 59056, France|Centre Henri Becquerel, Rouen, 76038, France|CH Yves Le Foll, Saint-Brieuc, 22000, France|H?pitaux Universitaires de Strasbourg, Strasbourg, 67091, France|IUCT Oncopole, Toulouse, 31059, France|H?pital Bretonneau, Tours, 37000, France|Centre Hospitalier de Troyes, Troyes, 10003, France|CH Valence, Valence, 26953, France|CHU Brabois, Vandoeuvre-les-Nancy, 54511, France Less << |
NCT06572982 | Acute Myeloid Leukemia | NOT_YET_RECRUITING | 2025-05-26 | - | |
NCT01201811 | Myelodysplastic Syndromes | PHASE4 | COMPLETED | 2013-05-01 | Changhua Christian Hospital, C... More >>hanghua, 500, Taiwan|Chiayi Chang Gung Memorial Hospital, Chiayi, 613, Taiwan|Buddhist Tzu Chi General Hospital-Hualien Tzu Chi Medical Center, Hualien, 970, Taiwan|Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, 833, Taiwan|Kaohsiung Medical Hospital University, Kaohsiung, 807, Taiwan|Shuang-ho Hospital, New Taipei City, 23561, Taiwan|China Medical University Hospital, Taichung, 404, Taiwan|National Cheng Kung University Hospital, Tainan, 704, Taiwan|National Taiwan University Hospital, Taipei, 10002, Taiwan|Taipei Veterans General Hospital, Taipei, 11217, Taiwan|Tri-Service General Hospital, Taipei, 11490, Taiwan Less << |
NCT01599325 | Myelodysplastic Syndrome (MDS) | PHASE2 | COMPLETED | 2018-03-13 | Peking University People's Hos... More >>pital, Beijing, 100044, China|The 301 Hospital- Chinese PLA General Hospital, Beijing, 300200, China|The Third Hospital of Peking University, Beijing, China|West China Hospital of Sichuan University, Chengdu, 610041, China|Guangdong General Hospital, Guangzhou, 510080, China|1st Hospital Zhejiang University (The First Affiliated Hospital of Zhejiang University ), Hangzhou, 310003, China|Ruijin Hospital Shanghai Jiaotong University, Shanghai, 200025, China|Shanghai 6th Hospital, Shanghai, 200233, China|The 1st Hospital of Soochow University, Suzhou, 215006, China|Blood Disease Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin, 300041, China|Wuhan Union Hospital, Wuhan, 430000, China Less << |
NCT00005934 | Beta Thalassemia | PHASE2 | COMPLETED | 2025-06-03 | National Institute of Diabetes... More >> and Digestive and Kidney Diseases (NIDDK), Bethesda, Maryland, 20892, United States Less << |
NCT01186939 | Myelodysplastic Syndromes | PHASE3 | COMPLETED | 2009-09-01 | East Melbourne, Victoria, Aust... More >>ralia|Herston, Australia|Perth, Australia|Woolloongabba, Australia|Plovdiv, Bulgaria|Aulnay Sous Bois Cedex, France|Berlin, Germany|Dusseldorf, Germany|Essen, Germany|Kiel, Germany|Heraklio, Crete, Greece|Haidari, Greece|Budapest, Hungary|Bologna, Italy|Firenze, Italy|Genova, Italy|Rome, Italy|Nijmegen, Netherlands|Lodz, Poland|Avda Campanar, Spain|Leon, Spain|London, United Kingdom Less << |
NCT01652781 | Myelodysplastic Syndrome | PHASE2 | UNKNOWN | 2025-12-16 | Seoul St. Mary's Hospital, Seo... More >>ul, 137-701, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of Less << |
NCT00384956 | Myelodysplastic Syndromes | PHASE2 | COMPLETED | 2025-03-10 | Washington University School o... More >>f Medicine, St. Louis, Missouri, 63110, United States Less << |
NCT00569660 | Myelofibrosis | PHASE2 | COMPLETED | 2025-04-08 | UT MD Anderson Cancer Center, ... More >>Houston, Texas, 77030, United States Less << |
NCT00350818 | Myelodysplastic Syndrome|Leuke... More >>mia Less << | PHASE1 | COMPLETED | 2025-08-10 | UT MD Anderson Cancer Center, ... More >>Houston, Texas, 77030, United States Less << |
NCT00739388 | Leukemia | PHASE2 | COMPLETED | 2025-11-12 | Kantonspital Aarau, Aarau, CH-... More >>5001, Switzerland|Kantonsspital Baden, Baden, CH-5404, Switzerland|Universitaetsspital-Basel, Basel, CH-4031, Switzerland|Oncology Institute of Southern Switzerland, Bellinzona, CH-6500, Switzerland|Inselspital Bern, Bern, CH-3010, Switzerland|Spitalzentrum Biel, Biel, CH-2500, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, CH-1011, Switzerland|Kantonsspital, Luzerne, Luzerne, CH-6000, Switzerland|Kantonsspital - St. Gallen, St. Gallen, CH-9007, Switzerland|Hopitaux Universitaires de Geneve, Thonex-Geneve, CH-1226, Switzerland|UniversitaetsSpital Zuerich, Zurich, CH-8091, Switzerland Less << |
NCT02447666 | Myelodysplastic Syndrome|Leuke... More >>mia, Myelomonocytic, Juvenile Less << | PHASE2 | COMPLETED | 2019-05-24 | St. Anna Kinderkrebsforschung,... More >> CHILDREN'S CANCER RESEARCH INSTITUTE, Vienna, 1090, Austria|Hopital Universitaire des Enfants, Brussels, 1020, Belgium|University Hospital Ghent, Ghent, 9000, Belgium|University Hospital Motol, Prague 5, 150 06, Czechia|Rigshospitalet, Copenhagen, DK-2100, Denmark|Centre Hospitalier Universitaire Lyon, Lyon, 69008, France|Hopital d'Enfants de la Timone, Marseille Cedex 01, 13005, France|Hopital Robert Debre, Paris, 75935, France|Klinikum Augsburg, Augsburg, 86156, Germany|Charite Berlin, Berlin, 13353, Germany|Universitaetsklinikum Carl Gustav Carus, Dresden, 01307, Germany|Hematology, Oncology and clinical immunology / Heinrich-Heine-University, Dusseldorf, 40225, Germany|Universitatsklinikum Essen, Essen, 45147, Germany|Klinikum der Johann Wolfgang Goethe-Universit?t Frankfurt/Main, Frankfurt am Main, 60596, Germany|Universitatsklinik, Freiburg, 79106, Germany|University of Hamburg, Hamburg, 20246, Germany|Medizinische Hochschule Hannover, Hannover, 30625, Germany|Universitatsklinikum, Jena, 7740, Germany|Universitatsklinikum Schleswig-Holstein, Kiel, 24105, Germany|Klinikum der Universitaet Muenchen, Munchen, 80336, Germany|Universitatsklinik Munster, Münster, 48149, Germany|Krankenhaus Barmherzige Bruder Regensburg, Regensburg, 93049, Germany|Universitatsklinikum, Tübingen, 72076, Germany|Our Lady's Hospital for Sick Children, Dublin 12, Ireland|Policlinico Sant'Orsola-Malpighi, Bologna, 40138, Italy|IRCCS Gaslini Hospital, Genova Quarto, 16148, Italy|Azienda Ospedaliera San Gerardo, Monza, 20900, Italy|General Hospital, Padova, 35128, Italy|IRCCS Policlinico San Matteo, Pavia, 27100, Italy|Ospedale Bambin Gesu, Roma, 00165, Italy|Regina Margherita Children's Hospital, Torino, 10126, Italy|Erasmus University Medical Center, Rotterdam, 3015 GJ, Netherlands|Hospital Sant Joan de Deu, Barcelona, 8950, Spain|Hospital Infantil Universitario Nino Jesus, Madrid, 28009, Spain|Hospital Universitario Virgen de La Arrixaca, Murcia, 30120, Spain|Queen Silvia Childrens Hospital, Gothenburg, SE-416 85, Sweden|Karolinska University Hospital, Stockholm, SE-171 76, Sweden|Universit?ts-Kinderklinik, Zurich, 8032, Switzerland|Royal Manchester Children's Hospital, Manchester, M13 9WL, United Kingdom Less << |
NCT00412919 | Multiple Myeloma | PHASE2 | TERMINATED | 2025-11-08 | The Alfred Hospital, Melbourne... More >>, Victoria, 3004, Australia Less << |
NCT00413478 | Chronic Lymphocytic Leukemia|L... More >>eukemia Less << | PHASE2 | TERMINATED | 2025-11-14 | University of Texas MD Anderso... More >>n Cancer Center, Houston, Texas, 77030, United States Less << |
NCT00887068 | Leukemia|AML|MDS | PHASE3 | COMPLETED | 2018-08-20 | University of Texas MD Anderso... More >>n Cancer Center, Houston, Texas, 77030, United States Less << |
NCT01747499 | Leukemia, Myeloid, Acute|Myelo... More >>dysplastic Syndromes|Precursor Cell Lymphoblastic Leukemia-Lymphoma Less << | PHASE1|PHASE2 | TERMINATED | 2018-12-24 | Washington University School o... More >>f Medicine, Saint Louis, Missouri, 63110, United States Less << |
NCT01050790 | Multiple Myeloma | COMPLETED | 2025-09-16 | Virginia Commonwealth Universi... More >>ty, Richmond, Virginia, 23298, United States Less << | |
NCT01338337 | Myelodysplastic Syndrome (MDS) | PHASE2 | COMPLETED | 2025-12-15 | Hospital General de Jerez, Jer... More >>ez, Cádiz, 11407, Spain|Hospital Costa del Sol, Marbella, Malaga, 29603, Spain|Hospital Reina Sofía, Servicio de Hematología, Cordoba, 14004, Spain|Hospital Universitario San Cecilio, Granada, 18012, Spain|Hospital Virgen de las Nieves, Granada, 18840, Spain|Hospital Juan Ramón Jiménez, Huelva, 21005, Spain|Hospital Carlos Haya, Malaga, 29800, Spain|Hospital Universitario Virgen del Rocío, Sevilla, 41013, Spain|Hospital Universitario Virgen de Valme, Sevilla, 41014, Spain Less << |
NCT06598332 | Graft-Versus-Host Disease(GVHD... More >>) Less << | EARLY_PHASE1 | NOT_YET_RECRUITING | 2029-02-01 | Houston Methodist Hospital, Ho... More >>uston, Texas, 77030, United States|Texas Children's Hospital, Houston, Texas, 77030, United States Less << |
NCT01305460 | Myelodysplastic Syndrome | PHASE1|PHASE2 | COMPLETED | 2015-11-16 | CHU d'Amiens, Amiens, 80054, F... More >>rance|Centre Hospitalier de La Cote Basque, Bayonne, 64100, France|H?pital Avicenne, Bobigny, 93009, France|Centre henri Mondor, Creteil, 94010, France|CHU Albert Michallon - Service d'Hématologie Clinique, Grenoble, 38043, France|Centre Hospitalier du Mans, Le Mans cedex, 72037, France|H?pital Huriez, Lille, 59037, France|H?pital Paoli Calmettes, Marseille, 13273, France|Centre Hospitalier de Meaux, Meaux, 77100, France|CHU Brabois, Nancy, 54511, France|CHU de nantes, Nantes, 44093, France|H?pital l'Archet de Nice, Nice, 06202, France|H?pital Cochin, Paris, 75004, France|H?pital Saint Louis, Paris, 75010, France|Hopital Saint Louis - AP-HP, Hematology Dpt, Paris, 75475, France|CHU de Haut-Lévèque, Pessac, 33604, France|CHU de Poitiers, Poitiers, 86021, France|CHRU Annecy Hospital, Pringy, 74374, France|H?pital Pontchaillou, Rennes, 35033, France|Hopital Purpan Service d'Hématologie Clinique, Toulouse, 31059, France|CH de Valence, Valence, 26953, France Less << |
NCT04891068 | Breast Cancer Female|Breast Ca... More >>ncer Invasive Less << | PHASE2 | RECRUITING | 2025-05-26 | University of Illinois Cancer ... More >>Center, Chicago, Illinois, 60612, United States Less << |
NCT02940483 | Brain Tumor Recurrent | EARLY_PHASE1 | COMPLETED | 2018-11-28 | UTHealth & Children's Memorial... More >> Hermann Hospital, Houston, Texas, 77030, United States Less << |
NCT00387647 | Leukemia | PHASE2 | COMPLETED | 2025-08-14 | H. Lee Moffitt Cancer Center a... More >>nd Research Institute, Tampa, Florida, 33612, United States|Duke University Medical Center, Durham, North Carolina, 27710, United States Less << |
NCT03666559 | Recurrent IDH1/2 Mutated Gliom... More >>a Less << | PHASE2 | ACTIVE_NOT_RECRUITING | 2024-03-23 | Pitie Salpetriere Hospital, Pa... More >>ris, 75013, France Less << |
NCT00446303 | Leukemia, Myelocytic, Acute|My... More >>elodysplastic Syndromes Less << | PHASE2 | TERMINATED | 2025-07-10 | CHU d'Amiens, Amiens, 80054, F... More >>rance|CHU Angers, Angers, 49033, France|CH d'Avignon, Avignon, 84000, France|CHU de Caen, Caen, 14033, France|Hopital d'Instruction des Armées Percy, Clamart, 92140, France|Hopital Henri Mondor, Creteil, 94000, France|CHU de Dijon, Dijon, 21034, France|CHU Albert Michallon, Grenoble, 38043, France|CHRU Hurriez, Lille, 59057, France|CHRU de Limoges, Limoges, 87046, France|Hopital Edouard Herriot, Lyon, 69437, France|Hopital Paoli Calmette, Marseille, 13273, France|Hopital Hotel Dieu, Nantes, 44093, France|Hopital Archet, Nice, 06202, France|Hopital Saint Louis, Paris, 75475, France|Hopital Saint Antoine, Paris, 75571, France|Hopital Cochin, Paris, 75679, France|Hopital Haut Leveque, Pessac, 33604, France|Hopital Jean-Bernard, Poitiers, 86021, France|CHRU de Reims, Reims, 51092, France|CHU Pontchaillou, Rennes, 35033, France|Hopital Hautepierre, Strasbourg, 67098, France|Hopital Purpan, Toulouse, 31031, France|CHU Brabois, Vandoeuvre, 54511, France|CH Versailles, Versailles, 78000, France Less << |
NCT00481273 | Myelodysplastic Syndromes | COMPLETED | 2010-08-31 | AVIDA Registry Help, Kansas Ci... More >>ty, Missouri, 66210, United States Less << | |
NCT01462578 | Acute Myelocytic Leukemia|Myel... More >>odysplastic Syndrome Less << | PHASE2 | COMPLETED | 2025-02-21 | Charité Campus Benjamin Frankl... More >>in, Berlin, Germany|Universit?tsklinikum Bonn, Bonn, Germany|Klinikum Chemnitz (Küchwald), Chemnitz, Germany|Universit?tsklinikum Carl Gustav Carus, Medizinische Klinik und Poliklinik I, Dresden, Germany|Universit?tsklinikum Essen, Klinik für H?matologie (Westdeutsches Tumorzentrum), Essen, Germany|Klinikum der J. W. Goethe-Universit?t, Medizinische Klinik II H?matologie / Onkologie, Frankfurt am Main, Germany|Universit?tsklinikum Freiburg, Freiburg, Germany|Universit?tsklinikum Heidelberg, Medizinische Klinik, Abt. Innere Medizin V, Heidelberg, Germany|Klinikum rechts der Isar der TU München, III. Med. Klinik und Poliklinik, München, Germany|LMU München, Klinikum Gro?hadern, Med. Klinik III, München, Germany|Universit?tsklinikum Münster, Innere Medizin A - KMT-Zentrum, Münster, Germany Less << |
NCT00728520 | Acute Myeloid Leukemia|Elderly | PHASE2 | UNKNOWN | 2025-06-12 | Kansas City Veterans Affairs M... More >>edical Center, Kansas City, Missouri, 64218, United States Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
4.09mL 0.82mL 0.41mL |
20.47mL 4.09mL 2.05mL |
40.95mL 8.19mL 4.09mL |